Thorac Cancer
-
This meta-analysis systematically evaluated the efficacy of PD-1 and PD-L1 inhibitors for the treatment of advanced non-small cell lung cancer (NSCLC) and investigated the efficacy of first-line therapy and PD-1 versus PD-L1 inhibitors. ⋯ PD-1/PD-L1 inhibitors significantly prolonged the OS of previously treated patients. No significant differences in OS were observed between PD-1 and PD-L1 inhibitors.
-
Single agent immune checkpoint inhibitors (ICIs) improve survival outcomes compared to chemotherapy for advanced non-small cell lung cancer (NSCLC), but treatment efficacy widely varies. The combination of ICIs with chemotherapy has shown promising efficacy over chemotherapy alone; however, whether this strategy is superior to single agent ICIs for the treatment of advanced NSCLC remains unknown. ⋯ Combing chemotherapy with ICIs improved treatment efficacy over ICIs alone. The additional efficacy of chemotherapy may differ between histological subtypes and EGFR mutation status.